Best known for her impact on pharmacogenomics testing becoming a standard of care, Dr. Becky Winslow is a nationally recognized leader in commercialization and clinical adoption strategies for in vitro diagnostics. As founder and president of inGENEious RX, Inc., Dr. Winslow partners with diagnostic companies to accelerate innovative tests from concept to routine clinical practice.
Previously, Dr. Winslow directed medication therapy management programs across retail, hospital, long-term care, and public health sectors for Walmart Inc., Community Health Systems, Inc., and the North Carolina Department of Health and Human Services. Her frustration with the limitations of traditional medication management tools fueled her passion for diagnostics that truly individualize patient care.
For over twelve years, Dr. Winslow has guided diagnostic stakeholders in advancing molecular diagnostics and therapeutic strategies to improve patient outcomes. She frequently presents at leading industry conferences such as the Association for Molecular Pathology and Lab Roots educational platforms.
She holds a Bachelor of Science in biology and a Doctor of Clinical Pharmacy degree from Campbell University and serves as a preceptor for Manchester University School of Pharmacy. Dr. Winslow’s work reflects a commitment to clinical innovation, healthcare transformation, and expanding patient access to high-value diagnostics.
